Company intelligence / Profile preview

C8 MediSensors

Los Gatos, California, United Statestouchendocrinology.com ↗

Ownership: Private
Development stage: Other

Overview

C8 MediSensors developed the first non-invasive continuous glucose monitor using Raman spectroscopy to measure blood glucose through the skin. Their flagship product, the HG1-c Optical Glucose Monitor System, received CE Mark approval in Europe in October 2012. Clinical studies showed accuracy comparable to early invasive CGMs but with less pain and risk. The company aimed to commercialize across Europe but did not achieve US regulatory approval and appears inactive as of recent years.

Therapeutic areas: Endocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

GE Healthcare

Beyond the preview

Go deeper on C8 MediSensors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C8 MediSensors.

Explore the full profile